News

AbstractTransthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a restrictive cardiac disease caused by the deposition of TTR in the heart. TTR is synthesized by…

At AstraZeneca, we turn ideas into life-changing medicines. Working here means being entrepreneurial, thinking big, and collaborating to make the impossible a…

AbstractTransthyretin amyloidosis (ATTR) is a multisystemic disorder associated with extracellular accumulation of misfolded transthyretin (TTR) protein forming…

Improved evaluation strategies are needed to recognize transthyretin cardiac amyloidosis (ATTR-CM) faster in patients presenting with heart failure (HF), especially…

AbstractFrontline therapy for systemic amyloid light chain (AL) amyloidosis has evolved significantly with the approval of daratumumab in combination with…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects older adults, and tafamidis has proven efficacy in reducing mortality and…

An artificial intelligence (AI) model that analyzes the results of echocardiograms may help predict the likelihood of transthyretin amyloid cardiomyopathy (ATTR-CM…

For the latest episode of the JNC CardioConnect podcast, Marcelo F. Di Carli, MD, MASNC, brought together 4 experts for a conversation about where the field of…

AbstractEarly diagnosis and accurate monitoring of disease progression are crucial for timely therapeutic intervention in hereditary transthyretin amyloidosis (…

FDA Grants Orphan Drug Designation to Zamubafusp AlfaAttralus, a clinical-stage biopharmaceutical company focused on systemic amyloidosis, has announced an…